Prostate cancer is the second most commonly diagnosed cancer in men and the fifth leading cause of cancer-related mortality worldwide, with over 1.5 million new cases and 397,000 deaths reported in 2022 [1]. Despite advancements in primary treatment, approximately 20–50% of patients initially treated with radical prostatectomy or radiotherapy with curative intent will experience biochemical recurrence